E. S. Antonarakis Et Al. , "Neoadjuvant randomized trial of degarelix (Deg) +/- cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).," 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , vol.35, Illinois, United States Of America, 2017
Antonarakis, E. S. Et Al. 2017. Neoadjuvant randomized trial of degarelix (Deg) +/- cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , (Illinois, United States Of America).
Antonarakis, E. S., Zahurak, M., Schaeffer, E. M., Partin, A. W., Ross, A., Allaf, M., ... Tosoian, J.(2017). Neoadjuvant randomized trial of degarelix (Deg) +/- cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP). . 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America
Antonarakis, Emmanuel Et Al. "Neoadjuvant randomized trial of degarelix (Deg) +/- cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).," 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, United States Of America, 2017
Antonarakis, Emmanuel S. Et Al. "Neoadjuvant randomized trial of degarelix (Deg) +/- cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).." 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , Illinois, United States Of America, 2017
Antonarakis, E. S. Et Al. (2017) . "Neoadjuvant randomized trial of degarelix (Deg) +/- cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).." 53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET , Illinois, United States Of America.
@conferencepaper{conferencepaper, author={Emmanuel S. Antonarakis Et Al. }, title={Neoadjuvant randomized trial of degarelix (Deg) +/- cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).}, congress name={53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET}, city={Illinois}, country={United States Of America}, year={2017}}